The prognosis and outcome of patients referred to an outpatient clinic for rheumatic diseases characterized by the presence of antinuclear antibodies (ANA).
To evaluate if patients with symptoms related to the musculoskeletal system, characterized by the presence of ANA, are prone to develop SLE or other specific rheumatic diseases, a follow-up study was started to investigate all patients who for the first time visited the outpatient clinic of the Department of Rheumatology in the period from 1983 to 1986 and who had detectable ANA. Patients with anti-dsDNA antibodies were excluded from evaluation. In total 65 patients could be included in the study, with a mean duration of follow-up of 9.3 years (range 2-16 years). During follow-up a specific rheumatic diagnosis could be established in 38 patients, on 75% of the patients within 2 years of follow-up, and in 90% within 5 years. Five patients developed a non-rheumatic disease. For the remaining 22 patients, diagnosis was not conclusive. These patients without a conclusive diagnosis had a mild clinical picture, which remained stable during follow-up. In conclusion 58% of patients presented with rheumatic symptoms and detectable ANA developed an overt rheumatic disease, usually within the first 5 years of follow-up.
Dijkstra
S
S
Department of Internal Medicine, Zuiderziekenhuis, Rotterdam, The Netherlands.
Nieuwenhuys
E J
EJ
Swaak
A J
AJ
D000974:Antibodies, Antinuclear / Q000032:analysis*; D003240:Connective Tissue Diseases / Q000175:diagnosis* / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D009426:Netherlands; D010044:Outpatient Clinics, Hospital; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear